Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Experimental & Molecular Medicine ; : 21-29, 2010.
Article in English | WPRIM | ID: wpr-104282

ABSTRACT

Angiotensin II is a major effector molecule in the development of cardiovascular disease. In vascular smooth muscle cells (VSMCs), angiotensin II promotes cellular proliferation and extracellular matrix accumulation through the upregulation of plasminogen activator inhibitor-1 (PAI-1) expression. Previously, we demonstrated that small heterodimer partner (SHP) represses PAI-1 expression in the liver through the inhibition of TGF-beta signaling pathways. Here, we investigated whether SHP inhibited angiotensin II-stimulated PAI-1 expression in VSMCs. Adenovirus-mediated overexpression of SHP (Ad-SHP) in VSMCs inhibited angiotensin II- and TGF-beta-stimulated PAI-1 expression. Ad-SHP also inhibited angiotensin II-, TGF-beta- and Smad3-stimulated PAI-1 promoter activity, and angiotensin II-stimulated AP-1 activity. The level of PAI-1 expression was significantly higher in VSMCs of SHP-/- mice than wild type mice. Moreover, loss of SHP increased PAI-1 mRNA expression after angiotensin II treatment. These results suggest that SHP inhibits PAI-1 expression in VSMCs through the suppression of TGF-beta/Smad3 and AP-1 activity. Thus, agents that target the induction of SHP expression in VSMCs might help prevent the development and progression of atherosclerosis.


Subject(s)
Animals , Humans , Mice , Rats , Adenoviridae/genetics , Angiotensin II/pharmacology , Blotting, Northern , Cells, Cultured , Electrophoretic Mobility Shift Assay , Genetic Vectors/genetics , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/drug effects , Plasminogen Activator Inhibitor 1/genetics , Promoter Regions, Genetic/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Reverse Transcriptase Polymerase Chain Reaction , Smad3 Protein/genetics , Transforming Growth Factor beta/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL